PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors (the "Private Placement"). The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses. The Company issued and sold an aggregate amount of 1,331,452 shares of its common s ...

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expens ...

Business Combination and Acquisitions - Carmell completed a business combination on July 14, 2023, with an exchange ratio of 0.06154 for Legacy Carmell common stock[14]. - The company acquired Axolotl Biologix for a total consideration of $57 million, based on a 30-day average daily VWAP of $7.05 per share[24]. - As of the closing date of the business combination, Alpha's trust account had a balance of $29,376,282 after redemptions totaling $29,374,372[15]. - The Forward Purchase Agreement involved the purchase of 1,705,959 shares of Class A Common Stock at a price of $10.28 per share, totaling $17,535,632[17]. - The Reset Price for the Forward Purchase Agreement is initially set at $11.50, with adjustments based on the VWAP Price of the shares[22]. Product Development and Pipeline - Carmell's product pipeline includes innovative regenerative bone and tissue healing products, alongside a line of men's products and topical haircare products[13]. - The company utilizes a proprietary formulation derived from allogeneic human platelets, containing over 1000 growth factors, proteins, and peptides, to support skin and hair health[28]. - Carmell's microemulsion formulations are designed to be non-comedogenic and do not use mineral or vegetable oils across its entire product line[31]. - The first cosmetic skincare product, Carmell G.L.E.E, was launched in March 2024, with nine additional products in the pipeline[34]. - The FDA granted fast-track designation for the BHA program, indicating potential to meet significant unmet needs[42]. - The company has submitted its BHA product candidate to the FDA as an Investigational New Drug for severe open tibia fractures[40]. - The company has conducted multiple preclinical studies supporting BHA's potential to heal wounds and accelerate bone healing[40]. - The company has twenty-one patents related to BHA and THA products, which include exclusive licenses from CMU[50]. Market Overview - The skincare and haircare markets were approximately $280 billion in 2022, expected to grow at a 6.4% CAGR[35]. - The beauty industry is concentrated, with significant retail sales generated by a few large multinational companies[37]. Regulatory Compliance and Safety - The company is subject to extensive FDA regulations, which continue after product approval, particularly regarding Good Manufacturing Practices (GMP)[63]. - The company must comply with various federal, state, and international laws impacting online business operations, including consumer protection and data privacy regulations[66]. - The company recognizes the importance of employee safety at manufacturing facilities and has programs in place to ensure compliance with environmental regulations[67]. - The company may face significant user fees under the Prescription Drug User Fee Act for its Biologics License Applications (BLAs)[61]. - The company is required to conduct post-marketing clinical trials to further assess the safety and effectiveness of its products[62]. - The company maintains policies to monitor and control environmental, health, and safety risks, ensuring compliance with applicable laws[70]. Operational Aspects - The company operates in one segment focused on the development and commercialization of bio-aesthetic and bone and tissue healing products[71]. - The company has nine full-time employees and one part-time employee as of March 15, 2024[72]. - The company has experienced no disruptions in its supply chain and actively works to anticipate and respond to potential disruptions[69]. - The company collaborates with suppliers to meet stringent design and creative criteria, ensuring adequate sources of supply for all products[68]. - The company is required to meet minimum performance requirements, including CE Mark submission by December 31, 2023, and FDA BLA submission by December 31, 2026[48].

PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "Th ...

PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced it will host an Investor Webinar titled "Unveiling the Secretome: On the Eve of Product Launch" on March 20, 2024 at 3:00 PM ET to discuss Carmell Secretome™, the biggest technological revolution in regenerative skin and haircare to the fast-growing ~$500 billion aesthetics industry. To register, click here. The event will fe ...

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell" or the "Company"), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024. Additionally, the Company is in advanced stages of development and testing of 9 other skincare products anticipated to launch over Spring and Summer 2024. The Carmell skincare product por ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 CARMELL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organiza ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Carmell Corporation (Exact name of registrant as specified in its charter) Delaware 001-40228 86-1645738 (State or other jurisdiction of incorporation) (Commission File Num ...

Table of Contents As filed with the Securities and Exchange Commission on August 7, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CARMELL CORPORATION (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 001-40228 86-1645738 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) ...

Table of Contents As filed with the Securities and Exchange Commission on August 7, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CARMELL CORPORATION (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 001-40228 86-1645738 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) ...